Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902233 | 1.00 | ATM (0.50) | ATMCTNNB1L3MBTL1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL9632609 | 0.98 | ATM (0.49) | ATMCTNNB1L3MBTL1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL9630734 | 0.98 | ATM (0.49) | ATMCTNNB1L3MBTL1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL7066174 | 0.98 | ATM (0.49) | ATMCTNNB1L3MBTL1TDP1KDM4E | |
| SCHEMBL8465002 | 0.87 | KMT2A (0.50) | CTNNB1L3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL7262986 | 0.87 | KMT2A (0.50) | CTNNB1L3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL3936305 | 0.87 | KMT2A (0.50) | CTNNB1L3MBTL1TDP1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL7257593 | 0.85 | KMT2A (0.49) | CTNNB1L3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL9848708 | 0.84 | CTNNB1 (0.60) | ATMCTNNB1L3MBTL1TDP1KDM4E | |
| SCHEMBL7311918 | 0.84 | CTSS (0.51) | ATMCTNNB1L3MBTL1TDP1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307428-B | Chiral alpha unnatural amino acid and preparation method thereof by rare noble metal complex | 北京元延医药科技股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-1957644-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| US-6552043-B1 | Useful as Calcitonin Gene-Related Peptide receptors; for therapy of migraine, pain, cardiovascular disorder, inflammation, diabetes, Reynaud's syndrome, peripheral arterial insufficiency, cranial hemorrhage and tumor | MERCK SHARPE & DOHME LTD. (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
| EP-1117662-A1 | BENZIMIDAZOLINYL PIPERIDINES AS CGRP LIGANDS | Merck Sharp & Dohme Limited (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018764-A1 | BENZIMIDAZOLINYL PIPERIDINES AS CGRP LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | ATM 4758/4885CTNNB1 1208/4885L3MBTL1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.